

Rodrigo Perez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7996743/publications.pdf>

Version: 2024-02-01

100
papers

7,175
citations

94433

37
h-index

56724

83
g-index

101
all docs

101
docs citations

101
times ranked

4638
citing authors

#	ARTICLE	IF	CITATIONS
1	Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy. <i>Annals of Surgery</i> , 2004, 240, 711-718.	4.2	1,473
2	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. <i>Lancet, The</i> , 2018, 391, 2537-2545.	13.7	677
3	Local Recurrence After Complete Clinical Response and Watch and Wait in Rectal Cancer After Neoadjuvant Chemoradiation: Impact of Salvage Therapy on Local Disease Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 822-828.	0.8	470
4	Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1109-1117.	1.3	393
5	Complete Clinical Response After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Characterization of Clinical and Endoscopic Findings for Standardization. <i>Diseases of the Colon and Rectum</i> , 2010, 53, 1692-1698.	1.3	341
6	Patterns of Failure and Survival for Nonoperative Treatment of Stage c0 Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2006, 10, 1319-1329.	1.7	336
7	Interval Between Surgery and Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Does Delayed Surgery Have an Impact on Outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1181-1188.	0.8	194
8	Increasing the Rates of Complete Response to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer: Results of a Prospective Study Using Additional Chemotherapy During the Resting Period. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1927-1934.	1.3	193
9	Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 90-101.	1.7	188
10	Transanal Endoscopic Microsurgery for Residual Rectal Cancer After Neoadjuvant Chemoradiation Therapy Is Associated With Significant Immediate Pain and Hospital Readmission Rates. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 545-551.	1.3	143
11	Loop Ileostomy Morbidity: Timing of Closure Matters. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1539-1545.	1.3	126
12	Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology, The</i> , 2021, 22, 43-50.	10.7	122
13	Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 3501-3511.	4.1	111
14	Transanal Endoscopic Microsurgery for Residual Rectal Cancer (ypT0-2) Following Neoadjuvant Chemoradiation Therapy. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 6-13.	1.3	108
15	Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 264-269.	1.3	104
16	The Role of Carcinoembriogenic Antigen in Predicting Response and Survival to Neoadjuvant Chemoradiotherapy for Distal Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1137-1143.	1.3	102
17	Nonoperative Approaches to Rectal Cancer: A Critical Evaluation. <i>Seminars in Radiation Oncology</i> , 2011, 21, 234-239.	2.2	101
18	Avoiding Radical Surgery Improves Early Survival in Elderly Patients With Rectal Cancer, Demonstrating Complete Clinical Response After Neoadjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 159-171.	1.3	98

#	ARTICLE	IF	CITATIONS
19	Absence of Lymph Nodes in the Resected Specimen After Radical Surgery for Distal Rectal Cancer and Neoadjuvant Chemoradiation Therapy: What does it Mean?. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 277-283.	1.3	90
20	Shifting concepts in rectal cancer management. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 173-202.	329.8	90
21	Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 925-933.	1.3	79
22	Optimal Timing for Assessment of Tumor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer: Do All Patients Benefit From Waiting Longer Than 6 Weeks?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1159-1165.	0.8	76
23	Strategies to improve clinical research in surgery through international collaboration. <i>Lancet, The</i> , 2013, 382, 1140-1151.	13.7	68
24	Lymph Node Size in Rectal Cancer Following Neoadjuvant Chemoradiation—Can We Rely on Radiologic Nodal Staging After Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1278-1284.	1.3	66
25	Complete Clinical Response after Neoadjuvant Chemoradiation for Distal Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 829-845.	1.5	65
26	Baseline T Classification Predicts Early Tumor Regrowth After Nonoperative Management in Distal Rectal Cancer After Extended Neoadjuvant Chemoradiation and Initial Complete Clinical Response. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 586-594.	1.3	63
27	Nonoperative Management of Rectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 135-151.	2.2	62
28	Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. <i>BMC Medical Genomics</i> , 2014, 7, 68.	1.5	58
29	Intratumoral Genetic Heterogeneity in Rectal Cancer. <i>Annals of Surgery</i> , 2017, 265, e4-e6.	4.2	56
30	Evaluating Causes of Death in Familial Adenomatous Polyposis. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1943-1949.	1.7	53
31	Transanal Endoscopic Microsurgery (TEM) Following Neoadjuvant Chemoradiation for Rectal Cancer: Outcomes of Salvage Resection for Local Recurrence. <i>Annals of Surgical Oncology</i> , 2016, 23, 1143-1148.	1.5	53
32	Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. <i>International Journal of Colorectal Disease</i> , 2005, 20, 434-439.	2.2	52
33	The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. <i>Oncotarget</i> , 2015, 6, 38360-38371.	1.8	52
34	Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer. <i>Cancer Genetics</i> , 2015, 208, 319-326.	0.4	45
35	Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis. <i>International Journal of Colorectal Disease</i> , 2008, 23, 757-765.	2.2	42
36	Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. <i>Radiation Oncology</i> , 2016, 11, 24.	2.7	42

#	ARTICLE	IF	CITATIONS
37	Local Excision for ypT2 Rectal Cancer—Much Ado About Something. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1431-1440.	1.7	39
38	A better cell cycle target for gene therapy of colorectal cancer: Cyclin G. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 884-889.	1.7	38
39	Fragmented pattern of tumor regression and lateral intramural spread may influence margin appropriateness after TEM for rectal cancer following neoadjuvant CRT. <i>Journal of Surgical Oncology</i> , 2014, 109, 853-858.	1.7	38
40	New Strategies in Rectal Cancer. <i>Surgical Clinics of North America</i> , 2017, 97, 587-604.	1.5	38
41	Are histological alterations observed in the gallbladder precancerous lesions?. <i>Clinics</i> , 2010, 65, 143-150.	1.5	35
42	Abdominoperineal Excision. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 844-853.	1.3	34
43	Lateral Node Dissection in Rectal Cancer in the Era of Minimally Invasive Surgery: A Step-by-Step Description for the Surgeon Unacquainted with This Complex Procedure with the Use of the Laparoscopic Approach. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 1237-1240.	1.3	34
44	Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy. <i>Oncotarget</i> , 2014, 5, 9199-9213.	1.8	31
45	Semiquantitative Volumetry by Sequential PET/CT May Improve Prediction of Complete Response to Neoadjuvant Chemoradiation in Patients With Distal Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 805-812.	1.3	30
46	Local Excision Techniques for Rectal Cancer After Neoadjuvant Chemoradiotherapy: What Are We Doing?. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 228-239.	1.3	30
47	Laparoscopic Versus Standard Appendectomy Outcomes and Cost Comparisons in the Private Sector. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 1174-1181.	1.7	29
48	Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer?. <i>European Journal of Surgical Oncology</i> , 2018, 44, 93-99.	1.0	29
49	Extralevator Abdominal Perineal Excision Versus Standard Abdominal Perineal Excision: Impact on Quality of the Resected Specimen and Postoperative Morbidity. <i>World Journal of Surgery</i> , 2017, 41, 2160-2167.	1.6	25
50	Rectal and Pouch Recurrences After Surgical Treatment for Familial Adenomatous Polyposis. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 129-136.	1.7	24
51	Is Tailoring Treatment of Rectal Cancer the Only True Benefit of Long-Course Neoadjuvant Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 264-266.	1.3	24
52	Transanal Local Excision for Distal Rectal Cancer and Incomplete Response to Neoadjuvant Chemoradiation—Does Baseline Staging Matter?. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 1253-1259.	1.3	23
53	Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. <i>British Journal of Surgery</i> , 2018, 105, e192-e203.	0.3	20
54	Culture of <i>Gigartina Skottsbergii</i> (Rhodophyta) in Southern Chile. A Pilot Scale Approach. <i>Journal of Applied Phycology</i> , 2006, 18, 307-314.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Complete clinical response in rectal cancer: a turning tide. <i>Lancet Oncology</i> , The, 2016, 17, 125-126.	10.7	19
56	E2F1 somatic mutation within miRNA target site impairs gene regulation in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0181153.	2.5	18
57	18F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes. <i>Annals of Nuclear Medicine</i> , 2016, 30, 513-517.	2.2	17
58	Watch and wait after a clinical complete response in rectal cancer patients younger than 50 years. <i>British Journal of Surgery</i> , 2021, 109, 114-120.	0.3	16
59	Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1534-1540.	1.7	15
60	Pitfalls of transanal endoscopic microsurgery for rectal cancer following neoadjuvant chemoradiation therapy. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2014, 23, 63-69.	1.2	15
61	Predicting Response to Neoadjuvant Treatment for Rectal Cancer: A Step Toward Individualized Medicine. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1057-1058.	1.3	14
62	Clinicopathologic and Immunohistochemistry Characterization of Synchronous Multiple Primary Gastric Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 233-239.	1.7	13
63	Quality of Life in Patients With Rectal Cancer After Chemoradiation: Watch-and-Wait Policy Versus Standard Resection—Are We Comparing Apples to Oranges?. <i>Diseases of the Colon and Rectum</i> , 2018, 61, e21-e21.	1.3	13
64	Should We Give Up The Search for a Clinically Useful Gene Signature for the Prediction of Response of Rectal Cancer to Neoadjuvant Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 895-897.	1.3	12
65	Watch and wait: Why, to whom and how. <i>Surgical Oncology</i> , 2022, 43, 101774.	1.6	12
66	Instalação e resultados preliminares de programa de rastreamento populacional de câncer colorretal em município brasileiro. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2008, 21, 12-15.	0.5	10
67	INTERESFINCTERIAL LIGATION OF FISTULA TRACT (LIFT) FOR PATIENTS WITH ANAL FISTULAS: A BRAZILIAN BI-INSTITUTIONAL EXPERIENCE. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2017, 30, 235-238.	0.5	8
68	The Future of Rectal Cancer Surgery: A Narrative Review of an International Symposium. <i>Surgical Innovation</i> , 2018, 25, 525-535.	0.9	8
69	The need for effective radiosensitizing agents. <i>Anti-Cancer Drugs</i> , 2011, 22, 308-310.	1.4	7
70	Management of adenomas within the area of rectal cancer that develop complete pathological response. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1285-1287.	2.2	7
71	No Surgery After Chemoradiation Is Not Equal to Nonoperative Management After Complete Clinical Response and Chemoradiation. <i>Journal of Clinical Oncology</i> , 2016, 34, 4051-4051.	1.6	7
72	ICRmax: An optimized approach to detect tumor-specific interchromosomal rearrangements for clinical application. <i>Genomics</i> , 2015, 105, 265-272.	2.9	4

#	ARTICLE	IF	CITATIONS
73	MRI Linac and How It May Potentially Lead to More Complete Response in Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 643-644.	1.3	4
74	Why Do We Need Another Tumor Regression Grading System for Rectal Cancer After Neoadjuvant Therapy?. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 1-2.	1.3	3
75	Laparo-endoscopic Transanal Total Mesorectal Excision (TATME): evidence of a novel technique. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2016, 25, 278-287.	1.2	3
76	Esplenose mimetizando gist: relato de caso e revisão da literatura. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2011, 24, 183-185.	0.5	3
77	Anal cancer: leading the way. <i>Lancet Oncology</i> , The, 2017, 18, 276-277.	10.7	2
78	Nodal status and survival in anal cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1292-1293.	10.7	2
79	Education levels and survival in colorectal cancer: is there really an obvious association?. <i>Intestinal Research</i> , 2020, 18, 247-248.	2.6	2
80	Radical surgery for colorectal metastatic melanoma. <i>International Journal of Colorectal Disease</i> , 2005, 20, 292-293.	2.2	1
81	Watch and wait strategy for distal rectal cancer after neoadjuvant CRT: A single institution's experience of 15 years in complete tumor regression without surgery. <i>Journal of the American College of Surgeons</i> , 2008, 207, S20.	0.5	1
82	Influência da invasão tumoral da linha de anastomose na sobrevivência de pacientes com câncer de coto gástrico. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2008, 21, 55-60.	0.5	1
83	Contact Radiation Therapy for Achieving Organ Preservation in Rectal Cancer After Standard Neoadjuvant Chemoradiation: Looking for a Place in the Sun. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 574-576.	0.8	1
84	In Regard to Sun Myint et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 742-743.	0.8	1
85	Endogastric Surgery for Gastric Diseases – Simplifying Technical Aspects. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2007, 17, 407-412.	0.8	0
86	A expressão de genes reparadores do DNA nos tumores sincrânicos de câncer colorretal esporádico. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2007, 20, 12-16.	0.5	0
87	In Reply to Sole and Calvo. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 933-934.	0.8	0
88	Complete Clinical Response after Neoadjuvant Chemoradiotherapy Managed Nonoperatively Results in Better Anorectal Function When Compared with Other Sphincter-Saving Alternatives for Distal Rectal Cancer. <i>Journal of the American College of Surgeons</i> , 2015, 221, S29-S30.	0.5	0
89	What more do we want from neoadjuvant treatment strategies in rectal cancer?. <i>Colorectal Cancer</i> , 2015, 4, 1-4.	0.8	0
90	Inferior Survival Rates After Chemoradiation for Rectal Cancer Without Surgery. <i>JAMA Oncology</i> , 2017, 3, 859.	7.1	0

#	ARTICLE	IF	CITATIONS
91	Es tiempo de reconsiderar la microcirugía endoscópica transanal tras quimio-radioterapia neoadyuvante para el cáncer rectal en pacientes altamente seleccionados. Cirugía Española, 2017, 95, 179-180.	0.2	0
92	New Horizons in Rectal Cancer Management. Clinics in Colon and Rectal Surgery, 2017, 30, 293-294.	1.1	0
93	Organ-preservation strategies in rectal cancer: advances and challenges. Colorectal Cancer, 2017, 6, 71-74.	0.8	0
94	The Estimate of the Impact of Coccyx Resection in Surgical Field Exposure During Abdominal Perineal Resection Using Preoperative High-Resolution Magnetic Resonance. World Journal of Surgery, 2018, 42, 3765-3770.	1.6	0
95	Chemoradiation Therapy: Nonoperative Approaches. , 2010, , 249-265.		0
96	Neoadjuvant Chemoradiation and Complete Clinical Response for Distal Rectal Cancer. Radiation Medicine Rounds, 2010, 1, 335-348.	0.0	0
97	Abstract A33: The use of personalized biomarkers for accessing tumor regression and defining surgical approach in rectal cancer patients treated with neoadjuvant chemoradiation.. , 2013, , .		0
98	Abstract A133: Genetic heterogeneity in rectal cancer: Identification of subpopulations of tumor cells resistant to neoadjuvant CRT.. , 2013, , .		0
99	Abstract 05: Genetic heterogeneity in rectal cancer - Identification of subpopulations of tumor cells resistant to neoadjuvant CRT. , 2016, , .		0
100	Abstract 391: Implications of Akt inhibition for neoadjuvant radiotherapy: improving the rectal cancer treatment. , 2016, , .		0